Ranjhan Gopang, MD
Internal Medicine · Carrollton, KYNPI 1720051865
Payments from drug & device makers
Across 224 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$332
- Amgen$281
- Johnson & Johnson$239
- Lilly USA, LLC$186
- Novartis$102
- plus $910 from 24 others
What the payments were for
- Food & beverage$3,38399%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 92 | $1,362 |
| GSK | 23 | $332 |
| Amgen | 19 | $281 |
| Johnson & Johnson | 13 | $239 |
| Lilly USA, LLC | 12 | $186 |
| Novartis | 6 | $102 |
| Boston Scientific | 5 | $96 |
| Esperion Therapeutics, Inc. | 7 | $91 |
| Bayer | 4 | $68 |
| Merck | 4 | $59 |
| E.r. Squibb & Sons, L.L.C. | 4 | $59 |
| Pfizer | 4 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Astellas Pharma US Inc | 3 | $47 |
| Novo Nordisk | 3 | $45 |
| Dexcom, Inc. | 3 | $42 |
| Boehringer Ingelheim | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Medtronic | 2 | $31 |
| AstraZeneca | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Medline Industries LP | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Acera Surgical, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Evoke Pharma, Inc. | 1 | $13 |
How this compares
$3,415 in reported general payments places this provider in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 112 | $132,112 |
| HumiraAdalimumab | 16 | $114,183 |
| EliquisApixaban | 111 | $92,526 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 102 | $87,060 |
| XareltoRivaroxaban | 54 | $61,538 |
| Breo ElliptaFluticasone/Vilanterol | 88 | $55,383 |
| JardianceEmpagliflozin | 36 | $54,029 |
| FarxigaDapagliflozin Propanediol | 36 | $53,918 |
| EntrestoSacubitril/Valsartan | 30 | $35,967 |
| Spiriva HandihalerTiotropium Bromide | 33 | $23,870 |
| LinzessLinaclotide | 23 | $21,825 |
| Bydureon BciseExenatide Microspheres | 18 | $21,119 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 82 | $20,791 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $13,490 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $12,876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $332 | $163,318227 claims |
| AbbVieHumira, Linzess | $1,362 | $136,00839 claims |
| Novo NordiskOzempic | $45 | $132,112112 claims |
| PfizerEliquis | $51 | $92,526111 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $29 | $79,434101 claims |
| Johnson & JohnsonXarelto | $239 | $61,53854 claims |
| Boehringer IngelheimJardiance | $32 | $54,02936 claims |
| NovartisEntresto | $102 | $35,96730 claims |
| Lilly USA, LLCTrulicity | $186 | $11,98013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Carrollton
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Bernard BuchananOwensboro$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.